First National Corp Neurocrine Biosciences Inc Transaction History

First National Corp

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Jul 30, 2019	SELL	$72.24 - $91.27 $3,250 - $4,107	-45 Closed	0 $0
Q1 2019 Jun 12, 2019	BUY	$69.31 - $91.53 $3,118 - $4,118	45 New	45 $5,000

647

95.3M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of First National Corp , based on Form 13F filings with the SEC.

Stay updated on First National Corp with notifications on news.